Restorative or Disruptive? Effects of Antidepressants on Sleep Architecture in Depression.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms and sleep effects without systematic synthesis
PubMed 42098542 · doi:10.1007/s40263-026-01297-6
What was done
This narrative review synthesized literature on the class-specific effects of antidepressant pharmacotherapy on sleep architecture (including REM latency, REM density, slow-wave sleep, and overall sleep continuity) in individuals with depression.
What was found
The abstract reports no numerical data, effect sizes, or confidence intervals. Descriptively, selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) most consistently suppress REM sleep and cause sleep fragmentation. In contrast, receptor-modulating and melatonergic agents (such as mirtazapine and agomelatine) preserve restorative sleep stages and improve circadian alignment. Alterations in REM sleep are described as potential markers of antidepressant response.
Why it matters
Selecting antidepressants based on their distinct profiles of sleep disruption or preservation allows clinicians to tailor treatment to individual symptom presentations and avoid therapy-induced daytime fatigue.
Limits
The abstract provides no systematic search methodology, study count, sample sizes, or quantitative data. Specific drug dosages, treatment durations, and the methodological quality of the underlying literature are not detailed.
Cited by
- supports Antidepressants such as SSRIs can eliminate 50% to 75% of nightly REM sleep.